Why the Right Clot Gets the Right Drug: Antiplatelets vs. Anticoagulants

A deep dive into the haemodynamics of thrombosis and why location is everything in treatment

If you've ever wondered why a patient with a heart attack is rushed aspirin while someone with a deep vein thrombosis (DVT) is started on heparin — and not the other way around — the answer lies in one of the most elegant intersections of physics and biology in all of medicine: the relationship between blood flow and clot formation.

It turns out that where a clot forms determines how it forms, and that determines what will dissolve it.

Two Systems, Two Clots

Blood clotting — or haemostasis — is not a single, monolithic process. It relies on two overlapping systems that work in concert:

Primary haemostasis involves platelets. When a vessel wall is damaged, platelets rush to the site, stick to exposed collagen, activate, and aggregate into a temporary "platelet plug."

Secondary haemostasis involves the coagulation cascade — a sequential activation of clotting factors (proteins in the plasma) that ultimately produces fibrin, a tough, mesh-like protein that reinforces and stabilises the platelet plug.

Both systems contribute to every clot to some extent. But here is the critical insight: the relative contribution of each system depends heavily on the local haemodynamic environment — specifically, the speed and turbulence of blood flow.

Arterial Clots: Born Under Pressure

Arteries carry oxygenated blood away from the heart under high pressure and at high velocity. The shear stress on arterial walls is intense.

When an arterial wall is disrupted — most commonly by the rupture of an atherosclerotic plaque — platelets are exposed to a sudden, turbulent, high-shear environment. Under these conditions, platelets are king. High shear stress actually activates platelets, triggering the release of ADP and thromboxane A₂, which recruit even more platelets in a rapid, self-amplifying cascade.

The result is a "white thrombus" — a dense, platelet-rich clot that forms fast and hard against the vessel wall. The coagulation cascade does participate, but there is simply too much turbulence and too much flowing blood washing away the soluble clotting factors for fibrin to be the dominant structural element.

Anticoagulants, by contrast, target the coagulation cascade — which is not the primary driver in this high-shear environment. Using an anticoagulant alone in acute arterial thrombosis would be like trying to stop a brick wall from being built by taking away the cement, when most of the wall is actually held together with structural steel.

Venous Clots: A Slow, Fibrin-Rich Conspiracy

Veins are a different world entirely. They carry deoxygenated blood back to the heart under low pressure and at low velocity. In certain regions — behind venous valves, in the deep veins of the legs during prolonged immobility — blood can become nearly stagnant.

This stasis is the perfect incubator for the coagulation cascade. Without the constant washing effect of fast-moving blood, activated clotting factors accumulate locally and the cascade runs to completion, generating enormous amounts of thrombin — the central enzyme of coagulation — which converts fibrinogen into fibrin.

The result is a "red thrombus" — a fibrin-rich, red blood cell-laden clot that looks more like a blood jelly than the compact platelet plug seen in arteries. Platelets are present, but they are largely passive bystanders rather than the primary architects.

Antiplatelets, in contrast, would have little impact on a process that is fundamentally driven by fibrin, not platelet aggregation. Aspirin does not stop thrombin from making fibrin.

The "Virchow's Triad" Lens

This all makes beautiful sense through the lens of Virchow's Triad, the classic framework describing the three conditions that predispose to thrombosis:

Factor	Arterial Relevance	Venous Relevance
Endothelial injury	Primary trigger (plaque rupture)	Less dominant
Abnormal blood flow	High shear → platelet activation	Stasis → factor accumulation
Hypercoagulability	Minor contribution	Major contributor

Arterial thrombosis is principally a disease of vessel wall injury and abnormal high-shear flow. Venous thrombosis is principally a disease of stasis and hypercoagulability. The treatments follow directly from the pathophysiology.

Where It Gets Nuanced

Real clinical medicine is rarely perfectly binary, and this framework has important nuances and many situations warrant the use of combination therapy. Typically, when this happens, multiple specialists get involved — cardiology, hematology, vascular surgery.

The Bottom Line

The elegance of this distinction is that the treatment truly flows from the mechanism:

• High flow, high shear, endothelial injury → platelets dominate → use antiplatelets
• Low flow, stasis, hypercoagulability → coagulation cascade dominates → use anticoagulants

Understanding why a clot forms where it forms is, in the most practical sense, the first step to dissolving it.